Thompson Creek Metals Company Inc. (NYSE:TC) shares fell -4.99% in last trading session and ended the day at $0.47. TC Gross Margin is 19.10% and its has a return on assets of -8.50%. Thompson Creek Metals Company Inc. (NYSE:TC) quarterly performance is -16.84%.
Thompson Creek Metals Company (NYSE:TC)‘s stock had its “sell” rating reissued by equities researchers at Dundee Securities in a research report issued to clients and investors on Wednesday, Analyst Ratings.Net reports.
Columbia Sportswear Company (NASDAQ:COLM) ended the last trading day at $53.77. Company weekly volatility is calculated as 6.56% and price to cash ratio as 9.05. Columbia Sportswear Company (NASDAQ:COLM) showed a weekly performance of -3.41%.
Columbia Sportswear (NASDAQ: COLM) reported Q3 EPS of $1.28, $0.19 better than the analyst estimate of $1.09. Revenue for the quarter came in at $767.6 million versus the consensus estimate of $738.73 million. Columbia Sportswear sees FY2015 EPS of $2.32-$2.37, versus the consensus of $2.35.
On 29 October, Maxim Integrated Products, Inc. (NASDAQ:MXIM) shares fell -2.90% and was closed at $40.79. MXIM EPS growth in last 5 year was 12.20%. Maxim Integrated Products, Inc. (NASDAQ:MXIM) year to date (YTD) performance is 31.25%.
Maxim Integrated Products, Inc. (NASDAQ:MXIM) announced that Chief Financial Officer Bruce Kiddoo will be presenting at the 2nd Annual Bernstein Technology Innovation Summit in San Francisco. The presentation is scheduled to begin at 1:15pm Pacific Time on Thursday, November 5, 2015.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shares fell -3.15% in last trading session and ended the day at $2.77. IDRA has a return on assets of -54.70%. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) quarterly performance is -22.63%.
Fate Therapeutics, Inc. (NASDAQ:FATE) caters to the Healthcare space. Its weekly performance is 36.39%. On the last day of trading company shares ended up at $4.46. Fate Therapeutics, Inc. (NASDAQ:FATE) distance from 50-day simple moving average (SMA50) is 0.59%.
Fate Therapeutics, Inc. (NASDAQ:FATE), announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,169,490 on October 27, 2015. The compositions described in the patent are foundational to the generation of induced pluripotent cells, which are a source of cells offering unique potential for off-the-shelf adoptive immunotherapy.
Leave a Reply